A Marked Response to Immunosuppressive Intervention for Abruptly Occurring Cardiac Complications in a Case of Juvenile Systemic Sclerosis Overlapped with Dermatomyositis

Table 1

Results of laboratory examinations at the time of admission.

		(Normal)
WBC	6000 (μl)	(3300–8800)
Neutrophil	46.7 (%)	(49–72)
Lymphocyte	47.0 (%)	(24–38)
Monocyte	3.7 (%)	(1.7–8.7)
RBC	455 (10^4/μL)	(386–492)
Hb	13.0 (g/dl)	(11.6–14.8)
Ht	37.9 (%)	(35.1–44.4)
Plt	22.6 (10^4/μL)	(15.8–34.8)
PT	13.1 (sec)	(9–13)
APTT	36.6 (sec)	(23–40)
FIB	195 (mg/dl)	(150–400)
D-dimer	<0.5 (μg/ml)	(<1.0)
TP	6.3 (mg/dl)	(6.6–8.1)
ALB	4.3 (mg/dl)	(4.1–5.1)
Tbil	0.4 (mg/dl)	(0.4–1.5)
TC	154 (mg/dl)	(142–248)
TG	139 (mg/dl)	(30–117)
ALP	372 (U/L)	(106–322)
AST	34 (U/L)	(13–30)
ALT	20 (U/L)	(7–23)
LDH	271 (U/L)	(124–222)
γGTP	9 (U/L)	(9–32)
CK	648 (U/L)	(41–153)
MM	93 (%)	(95.8–100)
MB	6 (%)	(0–1.8)
BB	1 (%)	(0–2.7)
ALD	16.8 (U/L)	(6–11)
BUN	10.1 (mg/dl)	(8–20)
Cre	0.33 (mg/dl)	(0.46–0.79)
Na	141 (mEq/L)	(138–145)
K	4.1 (mEq/L)	(3.6–4.8)
Cl	105 (mEq/L)	(101–108)
Ferritin	46.4 (ng/ml)	(5–157)
CRP	<0.10 (mg/L)	(<0.14)
ESR	3 (mm/h)	(3–15)
IgG	1001.2 (mg/dl)	(861–1747)
IgA	57.1 (mg/dl)	(93–393)
IgM	151 (mg/dl)	(50–269)
NT-proBNP	50 (pg/ml)	(29–124)
Antinuclear antibody		(—)
Anti-dsDNA antibody		(—)
Anti-Ro/SSA antibody		(—)
Anti-La/SSB antibody		(—)
Anti-Sm antibody		(—)
Anti-CCP antibody		(—)
Anti-PM-Scl antibody		(—)
Anti-topoisomerase I antibody		(—)
Anti-RNA polymerase III antibody		(—)
Anti-centromere antibody		(—)
Anti-Jo-1 antibody		(—)
Anti-ARS antibody		(—)
Anti-Ku antibody		(—)
Anti-U1RNP antibody		(—)